Drugs / GEN2
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06391918 | Mar 2024 → Mar 2026 | cancer | GenVivo, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT04313868 | Jun 2014 → Dec 2023 | hepatocellular carcinoma, metastatic malignant neoplasm | GenVivo, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GEN2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06391918 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “GEN2 is a non-replicating off-the-shelf gene therapy vector product” NCT06391918 ↗ |
| Route | Intravenous | “peripheral IV infusion” NCT04313868 ↗ |